MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 4711-4720

  Wang, Ning ^a   Wei, Heng ^a   Yin, Duo ^a   Lu, Yanming ^a   Zhang, Yao ^a   Zhang, Qiao ^a   Ma, Xiaoxin ^a   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Cervical cancer; Cyclin D1a; MicroRNA 195; Proliferation

Indexed keywords

CYCLIN D1; CYCLIN D1A; CYCLINE; MESSENGER RNA; MICRORNA; MICRORNA 195; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CCND1 PROTEIN, HUMAN; MIRN195 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE S PHASE; CERVICAL CANCER CELL LINE; CLONOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIHA CELL LINE; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; BINDING SITE; CELL PROLIFERATION; GENE EXPRESSION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; UTERINE CERVIX TUMOR;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CELL PROLIFERATION; CYCLIN D1; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MICRORNAS; RNA INTERFERENCE; UTERINE CERVICAL NEOPLASMS;

EID: 84945551271     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4292-3     Document Type: Article

References (29)

1. Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M, et al. Vital signs: cervical cancer incidence, mortality, and screening—United States, 2007–2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004–9.
2. Wang SM, Qiao YL. Implementation of cervical cancer screening and prevention in China—challenges and reality. Jpn J Clin Oncol. 2015;45(1):7–11.
3. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer. 2005;15(5):727–46.
4. Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, et al. State of the science in cervical cancer: where we are today and where we need to go. Cancer. 2014;120(15):2282–8.
5. Ramirez PT, Pareja R, Rendon GJ, Millan C, Frumovitz M, Schmeler KM. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? Gynecol Oncol. 2014;132(1):254–9.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
7. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167–79.
8. Bhardwaj A, Singh S, Singh AP. MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol. 2010;2(5):213–9.
9. He JF, Luo YM, Wan XH, Jiang D. Biogenesis of miRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol. 2011;25(6):404–8.
10. Liu L, Chen L, Xu Y, Li R, Du X. MicroRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 2010;400(2):236–40.
11. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of miR-195 and miR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011;17(7):1722–30.
12. Lin Y, Wu J, Chen H, Mao Y, Liu Y, Mao Q, et al. Cyclin-dependent kinase 4 is a novel target in microRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett. 2012;586(4):442–7.
13. Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro Oncol. 2012;14(3):278–87.
14. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology. 2009;50(1):113–21.
15. Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K, Kawada N. Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol. 2011;226(10):2535–42.
16. Hui W, Yuntao L, Lun L, WenSheng L, ChaoFeng L, HaiYong H, et al. MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS One. 2013;8(1), e54932.
17. Park H, Lee MJ, Jeong JY, Choi MC, Jung SG, Joo WD, et al. Dysregulated microRNA expression in adenocarcinoma of the uterine cervix: clinical impact of miR-363-3p. Gynecol Oncol. 2014;135(3):565–72.
18. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20), e179.
19. Oppitz U, Schulte S, Stopper H, Baier K, Muller M, Wulf J, et al. In vitro radiosensitivity measured in lymphocytes and fibroblasts by colony formation and comet assay: comparison with clinical acute reactions to radiotherapy in breast cancer patients. Int J Radiat Biol. 2002;78(7):611–6.
20. Massague J. G1 cell-cycle control and cancer. Nature. 2004;432(7015):298–306.
21. Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Ann Bot. 2011;107(7):1127–40.
22. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24(4):652–7.
23. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010;251(3):499–505.
24. Hansen J, Bross P. A cellular viability assay to monitor drug toxicity. Methods Mol Biol. 2010;648:303–11.
25. Liu D, Feng X, Wu X, Li Z, Wang W, Tao Y, et al. Tumor suppressor in lung cancer 1 (TSLC1), a novel tumor suppressor gene, is implicated in the regulation of proliferation, invasion, cell cycle, apoptosis, and tumorigenicity in cutaneous squamous cell carcinoma. Tumour Biol. 2013;34(6):3773–83.
26. Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003;36(1):60–5.
27. Arato-Ohshima T, Sawa H. Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer. 1999;83(3):387–92.
28. Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia. 2004;9(1):95–104.
29. Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res. 2001;7(8):2387–95.